查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1663452

非處方 (OTC) 止痛藥市場，按藥品類型、給藥途徑、配銷通路、國家和地區 - 2025 年至 2032 年全球行業分析、市場規模、市場佔有率和預測

Over-the-Counter (OTC) Pain Medication Market, By Drug Type, By Route of Administration, By Distribution Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 322 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告重點

2024 年非處方 (OTC) 止痛藥市場規模價值為 289.426 億美元，2025 年至 2032 年期間的複合年成長率為 4.20%。

此外，由於生活方式的改變和繁忙的日程安排導致的壓力水平升高，人們的頭痛、背痛和肌肉痛也隨之增加。因此，不服用處方藥而自行治療的趨勢日益成長。此外，由於配方創新減少了服藥頻率並提高了產品有效性，消費者對非處方藥的信心也增強了。在未來幾年，市場的成長可能會受到替代治療方案的可用性和對止痛藥負面影響的認知不斷提高的限制。

非處方 (OTC) 止痛藥市場 - 市場動態

全球範圍內慢性病發生率不斷上升

隨著全球慢性病的發生率不斷上升，非處方（OTC）止痛藥市場急劇成長。需要長期疼痛管理的慢性病（如關節炎、背痛、偏頭痛和頭痛）的數量一直在穩定增加。據認為，全世界有近 60% 的人患有慢性疼痛問題。隨著壽命延長，與年齡相關的身體機能障礙的普遍性也增加了慢性疼痛的可能性。勞動力老化、生活忙碌、工作負擔過重以及缺乏體力活動也加劇了這個問題。由於非處方藥（OTC）隨時可用、價格合理且不需要處方，因此患有慢性疼痛的人經常求助於它們來緩解偶爾或長期的疼痛。據藥局稱，對布洛芬、對乙醯氨基酚以及外用凝膠和乳膏等知名商品的需求增加。儘管處方止痛藥也很常用，但由於對成癮性、耐受性和副作用的擔憂，非處方藥正成為更有吸引力的選擇。此外，為了防止過量使用鴉片類藥物或其他限制性麻醉劑，醫生建議將非處方藥作為輕度至中度疼痛的初始治療選擇。隨著慢性病在全球範圍內變得越來越普遍，非處方藥（OTC）預計將更頻繁地用於疼痛治療。

非處方 (OTC) 止痛藥市場 - 關鍵見解

根據我們的研究分析師的分析，預測期內（2025-2032 年），全球市場預計年複合成長率約為 4.20%

根據藥物類型細分，非類固醇抗發炎藥物類別預計將在 2024 年佔據最大市場佔有率

根據配銷通路細分，醫院藥房將成為 2024 年的領先細分市場

從地區來看，北美是 2024 年最大的收入來源

非處方（OTC）止痛藥市場-細分分析：

全球非處方（OTC）止痛藥市場根據藥品類型、給藥途徑、配銷通路和地區進行細分。

根據藥物類型，市場分為對乙醯氨基酚、非類固​​醇抗發炎藥和其他藥物。 2024 年，由於世界老齡化人口中疼痛相關疾病病例較多，非類固醇抗發炎藥物類別佔據主導地位。非類固醇抗發炎藥物經常用於緩解老年人經常報告的背痛、關節和肌肉不適以及身體部位腫脹或受損。根據人口趨勢，隨著預期壽命的增加，未來幾十年來已開發國家和發展中國家 65 歲及以上人口的數量將大幅增加。隨著年齡的成長，慢性疼痛也變得越來越常見。由於越來越多的老年人依賴非處方藥來緩解疼痛，非類固醇抗發炎藥物如今已成為許多家庭和藥櫃中的常見藥物。它們的廣泛可用性提高了它們在無需處方的情況下治療與年齡相關的不適方面的普及度以及其已證實的療效。

根據給藥途徑，市場分為局部給藥、口服給藥和非腸道給藥。 2024年，市場以口服類為主。這是因為，特別是對於偶爾發生的或間歇性的疼痛，口服藥是人們自行服用非處方藥最實用、最簡單的方法。無需塗抹藥膏或凝膠，只需吞服藥片或膠囊即可在任何地方治療疼痛。由於這項重要益處，片劑和液體等口服製劑現已成為自我治療最受歡迎的選擇。對於精力充沛、忙碌的消費者來說，方便用戶「隨時隨地」使用至關重要，因為他們在外出時可能會出現頭痛或輕微的肌肉拉傷。顧客可以對口服藥物的安全性和有效性更加放心，因為它們比外用藥物經過了更徹底的研究和測試。

非處方 (OTC) 止痛藥市場 - 地理洞察

2024 年，北美在全球非處方 (OTC) 止痛藥市場佔據主導地位。該地區完善的醫療保健體系和高度的消費者健康意識推動了非處方（OTC）止痛藥的需求。人口老化和慢性疼痛問題也影響持續消費。強而有力的藥品法規透過確保產品的品質和安全來增強消費者的信任。製造商的密集行銷和廣告活動也增加了消費。此外，知名製藥企業的存在和零售機構中 OTC 產品的廣泛供應鞏固了北美在非處方（OTC）止痛藥行業的主導地位。

然而，在整個預測期內，預計亞太地區的複合年成長率最快。預計亞太地區非處方（OTC）止痛藥市場將顯著發展，這主要歸功於該地區人口眾多、中產階級不斷壯大以及購買力不斷增強。隨著中國和印度等國家的可支配收入和城市化進程大幅提高，對非處方（OTC）止痛藥的需求也隨之增加。此外，自我藥療的文化傾向和常見疾病的流行也加速了市場的成長。製藥公司正專注於這個市場，並推出一系列非處方（OTC）止痛藥來滿足不斷成長的消費者群體。

非處方（OTC）止痛藥市場－競爭格局：

許多跨國製藥公司，包括強生、輝瑞、賽諾菲、利潔時Group Limited、拜耳公司、葛蘭素史克公司等，主導非處方（OTC）止痛藥市場的競爭環境。品牌標籤和通用標籤也很重要，因為它們提供了經濟實惠的替代方案。水楊酸鹽、對乙醯氨基酚和非類固醇抗發炎藥等鎮痛劑的市場定位受行銷策略、產品創新和監管因素的影響。全球市場趨勢、消費者偏好和分銷策略影響非處方（OTC）止痛藥的競爭。企業正在嘗試採取一些重要措施以獲得競爭優勢。例如，2023 年 10 月，比利時的 Hyloris Pharmaceuticals 宣布美國 FDA 批准了強效非鴉片類止痛藥 Maxigesic IV。 Maxigesic IV 與 AFT Pharmaceuticals 合作開發，旨在用作緩解輕度至中度疼痛和中度至重度疼痛的輔助藥物。這種術後輸液劑含有 300 毫克布洛芬和 1,000 毫克對乙醯氨基酚，可作為麻醉藥物的替代品。

近期發展

2024 年 3 月：美國 FDA 警告某些非處方外用止痛藥，不要在雷射除毛、紋身、穿孔和微晶換膚等美容手術之前、期間或之後用於緩解疼痛。六家企業因非法推廣這些商品而收到政府的警告信。

2023 年 1 月：天然止痛膠囊是 Medterra 的最新產品。 Medterra 天然止痛藥是一種經過專業驗證的植物性止痛藥，旨在減輕發炎、關節僵硬和肌肉不適，且不會產生非處方 (OTC) 替代品經常出現的不良副作用。

2022年8月：生物製藥公司Myovant Sciences和輝瑞宣布，MYFEMBREE（瑞盧戈利克斯、雌二醇和炔諾酮醋酸鹽）獲得美國FDA批准，作為每日一次的藥丸，用於治療停經前女性中度至重度子宮內膜異位症疼痛。該藥物最多可以服用 24 個月。此次批准還涵蓋了子宮肌瘤引起的月經過多出血的治療，並得到了一項開放標籤擴展研究和 3 期試驗的證據支持。

目錄

第 1 章：非處方 (OTC) 止痛藥市場概覽

  • 研究範圍
  • 市場估計年限

第 2 章：執行摘要

  • 市場片段
    • 非處方 (OTC) 止痛藥市場片段（按藥物類型）
    • 非處方 (OTC) 止痛藥市場片段（依給藥途徑）
    • 非處方 (OTC) 止痛藥市場片段（按配銷通路）
    • 非處方 (OTC) 止痛藥市場（按國家/地區分類）
    • 非處方 (OTC) 止痛藥市場片段（按地區）
  • 競爭洞察

第 3 章：非處方 (OTC) 止痛藥主要市場趨勢

  • 非處方 (OTC) 止痛藥市場促進因素
    • 市場促進因素的影響分析
  • 非處方 (OTC) 止痛藥市場限制
    • 市場限制的影響分析
  • 非處方 (OTC) 止痛藥市場機會
  • 非處方 (OTC) 止痛藥市場未來趨勢

第 4 章：非處方 (OTC) 止痛藥產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景規劃
  • 規範架構分析

第 5 章：非處方 (OTC) 止痛藥市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • 新冠肺炎疫情後影響分析
    • 表現最佳的市場區隔
    • 邊際成長領域
    • 最失敗的部分
    • 邊際損失市場區隔

第 6 章：非處方 (OTC) 止痛藥市場格局

  • 非處方 (OTC) 止痛藥市佔分析，2024 年
  • 按主要製造商分類的細分數據
    • 成熟玩家分析
    • 新興企業分析

第 7 章：非處方 (OTC) 止痛藥市場 - 依藥物類型

  • 概述
    • 按藥物類型分類的細分市場佔有率分析
    • 乙醯胺酚
    • 非類固醇抗發炎藥
    • 其他

第 8 章：非處方 (OTC) 止痛藥市場 - 依給藥途徑

  • 概述
    • 按給藥途徑分類的細分市佔率分析
    • 主題
    • 口服
    • 腸外

第 9 章：非處方 (OTC) 止痛藥市場 - 按配銷通路

  • 概述
    • 按配銷通路進行細分市場佔有率分析
    • 醫院藥房
    • 電子商務
    • 零售藥局
    • 居家護理
    • 其他

第 10 章：非處方 (OTC) 止痛藥市場 - 按地區分類

  • 介紹
    • 按地區分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美非處方 (OTC) 止痛藥主要製造商
    • 北美市場規模及預測（按國家/地區）
    • 北美市場規模及預測（按藥物類型）
    • 北美市場規模及預測（按給藥途徑）
    • 北美市場規模及預測（按配銷通路分類）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲非處方 (OTC) 止痛藥主要製造商
    • 歐洲市場規模及預測（按國家）
    • 歐洲市場規模及預測（依藥品類型）
    • 歐洲市場規模及預測（依管理途徑）
    • 歐洲市場規模及預測（依配銷通路分類）
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區非處方 (OTC) 止痛藥主要製造商
    • 亞太地區市場規模及預測（依國家）
    • 亞太市場規模及預測（依藥品類型）
    • 亞太市場規模及預測（依管理途徑）
    • 亞太市場規模及預測（按配銷通路分類）
    • 印度
    • 中國
    • 韓國
    • 日本
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲非處方 (OTC) 止痛藥主要製造商
    • 拉丁美洲市場規模及預測（按國家/地區）
    • 拉丁美洲市場規模及預測（依藥品類型）
    • 拉丁美洲市場規模及預測（按管理途徑）
    • 拉丁美洲市場規模及預測（按配銷通路分類）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲非處方 (OTC) 止痛藥主要製造商
    • 中東和非洲市場規模及預測（按國家/地區）
    • 中東和非洲市場規模及預測（依藥品類型）
    • 中東和非洲市場規模及預測（按管理路線分類）
    • 中東和非洲市場規模及預測（按配銷通路分類）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 其他地區

第 11 章：主要供應商分析-非處方 (OTC) 止痛藥產業

  • 競爭儀錶板
  • 公司簡介
    • Johnson & Johnson
    • Pfizer Inc.
    • Sanofi SA
    • Reckitt Benckiser Group plc
    • Bayer AG
    • GlaxoSmithKline plc
    • Novartis AG
    • Perrigo Company plc
    • Takeda Pharmaceutical Company Limited
    • Lupin Limited
    • Sun Pharmaceutical Industries Ltd.
    • Alkem Laboratories Ltd.
    • Cipla Ltd.
    • Dr. Reddy's Laboratories Ltd.
    • Glenmark Pharmaceuticals Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Boehringer Ingelheim International GmbH
    • Others

第 12 章：360 度分析師視角

第 13 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV4606

REPORT HIGHLIGHT

Over-the-Counter (OTC) Pain Medication Market size was valued at US$ 28,942.6 Million in 2024, expanding at a CAGR of 4.20% from 2025 to 2032.

Over-the-counter (OTC) medications are those that licensed pharmacists dispense without a prescription. Whether at home or work, people frequently turn to over-the-counter (OTC) pain medications to relieve even the smallest physical discomfort. Both generic and brand-name OTC pain relievers come in tablet, pill, cream, ointment, spray, and patch form. The most widely used over-the-counter painkiller, paracetamol, has no anti-inflammatory properties. In the central nervous system (CNS), paracetamol inhibits the production of prostaglandins. The first line of treatment for acute lower back pain has been suggested to be acetaminophen. Over the past few years, the market for over-the-counter painkillers has shown encouraging trends. OTC painkiller demand has been mostly driven by the world's growing population as well as the ageing population that is more susceptible to arthritis and joint pain.

Furthermore, people are experiencing increased headaches, back pain, and muscle aches as a result of elevated stress levels brought on by changing lifestyles and busy schedules. As a result, the tendency to self-medicate without prescription medications has grown. In addition, consumer confidence in over-the-counter medicines has increased due to formulation innovations that decrease dosage frequency and increase product effectiveness. In the upcoming years, the market's growth may be constrained by the availability of substitute treatment options and rising awareness of the negative effects of painkillers.

Over-the-Counter (OTC) Pain Medication Market- Market Dynamics

Increasing frequency of chronic illnesses worldwide

The market for over-the-counter (OTC) pain medications has grown dramatically as a result of the increasing frequency of chronic illnesses worldwide. The number of chronic conditions like arthritis, back pain, migraines, and headaches that need long-term pain management has been steadily increasing. Nearly 60% of people worldwide are thought to experience chronic pain issues. The likelihood of chronic pain is increased by the prevalence of age-related physical impairments brought on by longer lifespans. An ageing workforce, busy lives, an excessive workload, and a lack of physical activity are also exacerbating the issue. Because over-the-counter (OTC) drugs are readily available, reasonably priced, and do not require a prescription, people with chronic pain frequently turn to them for either episodic or long-term relief. The demand for well-known goods that comprise ibuprofen, acetaminophen, and topical gels and creams has increased, according to pharmacies. Even while prescription painkillers are also commonly used, OTC medications are becoming a more appealing option due to worries about addiction, tolerance, and adverse effects. Additionally, in order to prevent the overprescription of opioids or other restricted narcotics, doctors advise OTC pharmaceuticals as the initial therapeutic option for mild to moderate pain. Over-the-counter (OTC) drugs are expected to be used more frequently for pain treatment as chronic illnesses become more prevalent globally.

Over-the-Counter (OTC) Pain Medication Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 4.20% over the forecast period (2025-2032)

Based on drug type segmentation, the nonsteroidal anti-inflammatory drug category was predicted to show maximum market share in the year 2024

Based on distribution channel segmentation, hospital pharmacies were the leading segment in 2024

On the basis of region, North America was the leading revenue generator in 2024

Over-the-Counter (OTC) Pain Medication Market- Segmentation Analysis:

The Global Over-the-Counter (OTC) Pain Medication Market is segmented on the basis of Drug Type, Route of Administration, Distribution Channel, and Region.

Based on drug type, the market is divided into Acetaminophen, Nonsteroidal Anti-inflammatory Drug, and Others. In 2024, the nonsteroidal anti-inflammatory drug category held a dominant market share because of the high cases of pain-related disorders in the world's ageing population. NSAIDs are frequently used to alleviate backaches, joint and muscular discomfort, and swollen or damaged body parts that older adults frequently report. According to demographic trends, the number of people 65 and older will rise dramatically over the next several decades in both developed and developing countries as life expectancies rise. As people age, chronic pain also becomes increasingly common. NSAIDs are now commonplace in many homes and medicine cabinets due to the sizable and growing number of senior citizens who rely on over-the-counter drugs for pain management. Their extensive availability boosts their popularity for self-medication of age-related discomforts without a prescription and their demonstrated efficacy.

On the basis of the route of administration, the market is segregated into Topical, Oral, and Parenteral. In 2024, the market was dominated by the oral category. This is because, particularly for sporadic or intermittent pain, oral pills are the most practical and simplest way for people to self-administer over-the-counter pharmaceuticals. Pain treatment without the inconvenience of applying creams or gels is possible anywhere by swallowing tablets or capsules. Oral formulations, such as tablets and liquids, are now the most popular option for self-treatments due to this important benefit. Being user-friendly "on the go" is crucial for energetic, busy consumers who can have headaches or mild strained muscles while out and about. Customers can feel more secure about the safety and efficacy of oral medications because they have undergone more thorough research and testing than topical preparations.

Over-the-Counter (OTC) Pain Medication Market- Geographical Insights

In 2024, North America held a dominant position in the global market for Over-the-Counter (OTC) Pain Medication. The demand for over-the-counter (OTC) pain medications is fueled by the region's established healthcare system and high level of consumer health awareness. The ageing population and the cases of chronic pain problems also influence sustained consumption. Strong pharmaceutical laws promote consumer trust by guaranteeing the quality and safety of products. Manufacturers' intensive marketing and advertising campaigns also increase consumption. Furthermore, North America's dominant position in the over-the-counter (OTC) pain medications industry is reinforced by the existence of well-known pharmaceutical businesses and the extensive availability of OTC goods in retail establishments.

However, throughout the projected period, the Asia-Pacific region is anticipated to see the fastest CAGR. The market for over-the-counter (OTC) pain medications is expected to develop significantly in the Asia-Pacific region mainly because of its large population, growing middle class, and rising purchasing power. The demand for over-the-counter (OTC) pain medications has increased as a result of significant increases in disposable income and urbanization in nations like China and India. Additionally, a cultural propensity for self-medication and the prevalence of common illnesses have accelerated market growth. Pharmaceutical companies are focusing on this market and introducing a range of over-the-counter (OTC) painkillers to cater to the expanding consumer base.

Over-the-Counter (OTC) Pain Medication Market- Competitive Landscape:

Many multinational pharmaceutical companies, including Johnson & Johnson, Pfizer Inc., Sanofi S.A., Reckitt Benckiser Group plc, Bayer AG, GlaxoSmithKline plc, and others, dominate the competitive environment of the over-the-counter (OTC) pain medications market. Branded and generic labels are important as well since they provide affordable substitutes. The market placement of analgesic formulations, such as salicylate, acetaminophen, and NSAIDs, is influenced by marketing strategies, product innovations, and regulatory factors. Global market trends, consumer preferences, and distribution strategies influence Over-the-counter (OTC) pain medications competition. Businesses are attempting to put some important measures into place in order to get a competitive advantage. For instance, in October 2023, Belgium-based Hyloris Pharmaceuticals announced that the USFDA had approved the potent non-opioid pain reliever Maxigesic IV. Developed in partnership with AFT Pharmaceuticals, Maxigesic IV is designed to be used as an adjuvant for mild-to-moderate pain and moderate-to-severe pain. This postoperative infusion, which combines 300 mg of ibuprofen and 1,000 mg of paracetamol, offers an alternative to narcotic drugs.

Recent Development

March 2024: Certain over-the-counter topical analgesics have been cautioned by the U.S. FDA not to be used for pain relief prior to, during, or following cosmetic procedures such as laser hair removal, tattooing, piercing, and microdermabrasion. Six businesses received warning letters from the government for unlawfully promoting these goods.

January 2023: Natural Pain Relief capsules are Medterra's newest offering. A professionally validated plant-based pain reliever, Medterra Natural Pain Relief is designed to reduce inflammation, joint stiffness, and muscular discomfort without the unfavourable side effects that are frequently connected to over-the-counter (OTC) alternatives.

August 2022: The biopharmaceutical business Myovant Sciences and Pfizer announced that MYFEMBREE (relugolix, estradiol, and norethindrone acetate) was approved by the USFDA as a once-daily pill for the treatment of moderate to severe endometriosis pain in premenopausal women. The medication can be taken for up to 24 months. The clearance also covers treatment for excessive menstrual bleeding caused by uterine fibroids, and it is backed by evidence from an open-label extension study and Phase 3 trials.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL OVER-THE-COUNTER (OTC) PAIN MEDICATION MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Johnson & Johnson
  • Pfizer Inc.
  • Sanofi S.A.
  • Reckitt Benckiser Group plc
  • Bayer AG
  • GlaxoSmithKline plc
  • Novartis AG
  • Perrigo Company plc
  • Takeda Pharmaceutical Company Limited
  • Lupin Limited
  • Sun Pharmaceutical Industries Ltd.
  • Alkem Laboratories Ltd.
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Boehringer Ingelheim International GmbH
  • Others

GLOBAL OVER-THE-COUNTER (OTC) PAIN MEDICATION MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • Acetaminophen
  • Nonsteroidal Anti-inflammatory Drug
  • Others

GLOBAL OVER-THE-COUNTER (OTC) PAIN MEDICATION MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Topical
  • Oral
  • Parenteral

GLOBAL OVER-THE-COUNTER (OTC) PAIN MEDICATION MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • E-commerce
  • Retail Pharmacies
  • Home Care
  • Others

GLOBAL OVER-THE-COUNTER (OTC) PAIN MEDICATION MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Over-the-Counter (OTC) Pain Medication Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Over-the-Counter (OTC) Pain Medication Market Snippet by Drug Type
    • 2.1.2. Over-the-Counter (OTC) Pain Medication Market Snippet by Route of Administration
    • 2.1.3. Over-the-Counter (OTC) Pain Medication Market Snippet by Distribution Channel
    • 2.1.4. Over-the-Counter (OTC) Pain Medication Market Snippet by Country
    • 2.1.5. Over-the-Counter (OTC) Pain Medication Market Snippet by Region
  • 2.2. Competitive Insights

3. Over-the-Counter (OTC) Pain Medication Key Market Trends

  • 3.1. Over-the-Counter (OTC) Pain Medication Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Over-the-Counter (OTC) Pain Medication Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Over-the-Counter (OTC) Pain Medication Market Opportunities
  • 3.4. Over-the-Counter (OTC) Pain Medication Market Future Trends

4. Over-the-Counter (OTC) Pain Medication Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Over-the-Counter (OTC) Pain Medication Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Over-the-Counter (OTC) Pain Medication Market Landscape

  • 6.1. Over-the-Counter (OTC) Pain Medication Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Over-the-Counter (OTC) Pain Medication Market - By Drug Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Type, 2024 & 2032 (%)
    • 7.1.2. Acetaminophen
    • 7.1.3. Nonsteroidal Anti-inflammatory Drug
    • 7.1.4. Others

8. Over-the-Counter (OTC) Pain Medication Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
    • 8.1.2. Topical
    • 8.1.3. Oral
    • 8.1.4. Parenteral

9. Over-the-Counter (OTC) Pain Medication Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. E-commerce
    • 9.1.4. Retail Pharmacies
    • 9.1.5. Home Care
    • 9.1.6. Others

10. Over-the-Counter (OTC) Pain Medication Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Over-the-Counter (OTC) Pain Medication Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Over-the-Counter (OTC) Pain Medication Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.8. France
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.8.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.9. Italy
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.9.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.10. Spain
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.10.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.11. United Kingdom
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.3. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.11.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.11.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.12. Russia
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.13. Netherlands
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.14. Sweden
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.2. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.16. Rest of Europe
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.16.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.16.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Over-the-Counter (OTC) Pain Medication Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.9. South Korea
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.9.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.10. Japan
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.10.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Over-the-Counter (OTC) Pain Medication Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Over-the-Counter (OTC) Pain Medication Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Over-the-Counter (OTC) Pain Medication Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Johnson & Johnson
    • 11.2.2. Pfizer Inc.
    • 11.2.3. Sanofi S.A.
    • 11.2.4. Reckitt Benckiser Group plc
    • 11.2.5. Bayer AG
    • 11.2.6. GlaxoSmithKline plc
    • 11.2.7. Novartis AG
    • 11.2.8. Perrigo Company plc
    • 11.2.9. Takeda Pharmaceutical Company Limited
    • 11.2.10. Lupin Limited
    • 11.2.11. Sun Pharmaceutical Industries Ltd.
    • 11.2.12. Alkem Laboratories Ltd.
    • 11.2.13. Cipla Ltd.
    • 11.2.14. Dr. Reddy's Laboratories Ltd.
    • 11.2.15. Glenmark Pharmaceuticals Ltd.
    • 11.2.16. Teva Pharmaceutical Industries Ltd.
    • 11.2.17. Boehringer Ingelheim International GmbH
    • 11.2.18. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us